ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages

Multiple myeloma patients in the iMMagine-1 study were less heavily pretreated than in the CARTITUDE-1 trial of Carvykti, but Gilead noted that more patients receiving anito-cel had high-risk features.